Eric D Shah1, Hyungjin Myra Kim2, Philip Schoenfeld1,3. 1. Division of Gastroenterology, University of Michigan, Ann Arbor, MI, USA. 2. Center for Statistical Consultation and Research, University of Michigan, Ann Arbor, MI, USA. 3. John D. Dingell VA Medical Center, Detroit, MI, USA.
Abstract
OBJECTIVES: Linaclotide and plecanatide are guanylate cyclase-C (GCC) agonists for the treatment of chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C). Our objective is to evaluate the efficacy and tolerability of GCC agonists based on data from multiple randomized controlled trials (RCTs). METHODS: We searched PubMED, EMBASE, Cochrane databases, clinicaltrials.gov, major conference abstracts, Food and Drug Administration (FDA) websites, and United States Securities and Exchange Commission filings of drug sponsors to identify RCTs of CIC or IBS-C patients. We assessed efficacy based on FDA-approved composite responder endpoints, diarrhea as an adverse event, and study withdrawal owing to diarrhea for each therapy. Trial results were pooled using DerSimonian and Laird random effects model of meta-analysis and exact logistic regression when appropriate with 95% confidence intervals. Meta-regression was performed to compare outcomes between therapies adjusting for placebo event rate. RESULTS: Eight linaclotide trials (five CIC; three IBS-C) and seven plecanatide trials (four CIC; three IBS-C) evaluating 10,369 patients met inclusion criteria. FDA publications documented that different definitions for diarrhea were used in linaclotide vs. plecanatide trials. Both drugs were efficacious in treating CIC (linaclotide 72 μg (Odds ratio (OR)=3.11, 95% CI 1.81-5.34); linaclotide 145 μg (OR=3.25, 2.15-4.91); plecanatide 3 mg (OR=1.99, 1.57-2.51)) and IBS-C (linaclotide 290 μg (OR=2.43, 1.48-3.98); plecanatide 3 mg (OR=1.87, 1.47-2.38); plecanatide 6 mg (OR=1.92, 1.48-2.48)). Diarrhea occurred in excess of placebo in treating CIC (linaclotide 72 μg (OR=3.07, 1.97-4.77); linaclotide 145 μg (OR=3.70, 2.69-5.10); plecanatide 3 mg (OR=3.86, 1.83-8.12)) and IBS-C (linaclotide 290 μg (OR=8.02, 5.20-12.37); plecanatide 3 mg (OR=5.55, 1.62-19.00); plecanatide 6 mg (OR=4.13, 1.57-10.83)). Based on meta-regression, there were no statistically significant differences between therapies in odds ratios for efficacy, diarrhea, or diarrhea-related study withdrawals. CONCLUSIONS: Both linaclotide and plecanatide demonstrate similar efficacy and tolerability in treating IBS-C and CIC. No differences in odds of diarrhea were seen between linaclotide and plecanatide.
OBJECTIVES:Linaclotide and plecanatide are guanylate cyclase-C (GCC) agonists for the treatment of chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C). Our objective is to evaluate the efficacy and tolerability of GCC agonists based on data from multiple randomized controlled trials (RCTs). METHODS: We searched PubMED, EMBASE, Cochrane databases, clinicaltrials.gov, major conference abstracts, Food and Drug Administration (FDA) websites, and United States Securities and Exchange Commission filings of drug sponsors to identify RCTs of CIC or IBS-Cpatients. We assessed efficacy based on FDA-approved composite responder endpoints, diarrhea as an adverse event, and study withdrawal owing to diarrhea for each therapy. Trial results were pooled using DerSimonian and Laird random effects model of meta-analysis and exact logistic regression when appropriate with 95% confidence intervals. Meta-regression was performed to compare outcomes between therapies adjusting for placebo event rate. RESULTS: Eight linaclotide trials (five CIC; three IBS-C) and seven plecanatide trials (four CIC; three IBS-C) evaluating 10,369 patients met inclusion criteria. FDA publications documented that different definitions for diarrhea were used in linaclotide vs. plecanatide trials. Both drugs were efficacious in treating CIC (linaclotide 72 μg (Odds ratio (OR)=3.11, 95% CI 1.81-5.34); linaclotide 145 μg (OR=3.25, 2.15-4.91); plecanatide 3 mg (OR=1.99, 1.57-2.51)) and IBS-C (linaclotide 290 μg (OR=2.43, 1.48-3.98); plecanatide 3 mg (OR=1.87, 1.47-2.38); plecanatide 6 mg (OR=1.92, 1.48-2.48)). Diarrhea occurred in excess of placebo in treating CIC (linaclotide 72 μg (OR=3.07, 1.97-4.77); linaclotide 145 μg (OR=3.70, 2.69-5.10); plecanatide 3 mg (OR=3.86, 1.83-8.12)) and IBS-C (linaclotide 290 μg (OR=8.02, 5.20-12.37); plecanatide 3 mg (OR=5.55, 1.62-19.00); plecanatide 6 mg (OR=4.13, 1.57-10.83)). Based on meta-regression, there were no statistically significant differences between therapies in odds ratios for efficacy, diarrhea, or diarrhea-related study withdrawals. CONCLUSIONS: Both linaclotide and plecanatide demonstrate similar efficacy and tolerability in treating IBS-C and CIC. No differences in odds of diarrhea were seen between linaclotide and plecanatide.
Authors: Anthony J Lembo; Harvey A Schneier; Steven J Shiff; Caroline B Kurtz; James E MacDougall; Xinwei D Jia; James Z Shao; Bernard J Lavins; Mark G Currie; Donald A Fitch; Brenda I Jeglinski; Paul Eng; Susan M Fox; Jeffrey M Johnston Journal: N Engl J Med Date: 2011-08-11 Impact factor: 91.245
Authors: Robert W Busby; Alexander P Bryant; Wilmin P Bartolini; Etchell A Cordero; Gerhard Hannig; Marco M Kessler; Shalina Mahajan-Miklos; Christine M Pierce; Robert M Solinga; Li Jing Sun; Jenny V Tobin; Caroline B Kurtz; Mark G Currie Journal: Eur J Pharmacol Date: 2010-09-20 Impact factor: 4.432
Authors: Inmaculada Silos-Santiago; Gerhard Hannig; Helene Eutamene; Elena E Ustinova; Sylvie G Bernier; Pei Ge; Christopher Graul; Sarah Jacobson; Hong Jin; Elaine Liong; Marco M Kessler; Tammi Reza; Samuel Rivers; Courtney Shea; Boris Tchernychev; Alexander P Bryant; Caroline B Kurtz; Lionel Bueno; Michael A Pezzone; Mark G Currie Journal: Pain Date: 2013-06-05 Impact factor: 6.961
Authors: Jeffrey M Johnston; Caroline B Kurtz; Douglas A Drossman; Anthony J Lembo; Brenda I Jeglinski; James E MacDougall; Stephen M Antonelli; Mark G Currie Journal: Am J Gastroenterol Date: 2009-01 Impact factor: 10.864
Authors: Satish Rao; Anthony J Lembo; Steven J Shiff; Bernard J Lavins; Mark G Currie; Xinwei D Jia; Kelvin Shi; James E MacDougall; James Z Shao; Paul Eng; Susan M Fox; Harvey A Schneier; Caroline B Kurtz; Jeffrey M Johnston Journal: Am J Gastroenterol Date: 2012-11 Impact factor: 10.864
Authors: John C Flickinger; Jeffrey A Rappaport; Joshua R Barton; Trevor R Baybutt; Amanda M Pattison; Adam E Snook; Scott A Waldman Journal: Biomark Med Date: 2021-01-20 Impact factor: 2.851